To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Brain natriuretic peptide… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Brain natriuretic peptides in atherosclerotic renal artery stenosis and effects of renal angioplasty

Journal article
Authors Elzbieta Nowakowska-Fortuna
Aso Saeed
Gregor Guron
Michael Fu
Ola Hammarsten
Gert Jensen
Hans Herlitz
Published in Kidney and Blood Pressure Research
Volume 37
Issue 6
Pages 657-66
ISSN 1420-4096
Publication year 2013
Published at Institute of Biomedicine, Department of Clinical Chemistry and Transfusion Medicine
Institute of Medicine, Department of Molecular and Clinical Medicine
Pages 657-66
Language en
Keywords Brain natriuretic peptide Renal angioplasty, Renal artery stenosis, Renovascular hypertension, Adiponectin
Subject categories Clinical Medicine


Background: We hypothesized that plasma levels of brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) would be elevated, and adiponectin concentrations reduced, in patients with atherosclerotic renal artery stenosis (ARAS) and that BNPs might be used to identify patients who would benefit from percutaneous transluminal renal angioplasty (PTRA). Methods: Data were collected before renal angiography in 91 patients with hypertension and suspected ARAS (significant ARAS; n=47, and non-RAS; n=44) and in 20 healthy controls (C). In ARAS patients analyses were repeated four weeks after PTRA. Results: Ambulatory systolic blood pressure (ASBP) was significantly elevated in the ARAS group vs. both C and non-RAS groups. Baseline plasma BNP and NT-proBNP levels were significantly elevated, and adiponectin concentrations reduced, in the ARAS group vs. C but not vs. the non-RAS group. One month after PTRA, ASBP was reduced vs. baseline (149+/-16 to 139+/-15 mm p<0.01). Brain natriuretic peptides were not significantly affected by PTRA. Conclusions: Patients with ARAS showed elevated of BNP and NT-proBNP concentrations, and reduced levels of adiponectin, compared to healthy controls but not vs. hypertensive individuals without RAS. Our data do no support the use of BNP analyses in the identification of ARAS patients who will have a beneficial blood pressure response to PTRA. (c) 2014 S. Karger AG, Basel.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?